All right. Well, good morning, everyone. Thank you very much for joining us on our next session. I am Michael Yee, Senior Biotechnology Analyst and Global Head of Biotech Research here at UBS, and very pleased to have the Chief Executive Officer of Kodiak Sciences, Mr. Victor Perlroth, up here with us. Thank you so much. Great to see you, Victor.
Thanks, Mike. Good to be here.
It has been an exciting year for you. I think your stock is up massively this year, as you have put up a lot of positive data earlier this year and then recently too. Lots of phase III data, very de-risked, very exciting time. If all that was not enough, there is a second drug we are going to get data on too. Let us unpack that a little bit. Maybe you could just give us a brief introduction to Kodiak from the standpoint of what your lead drug is and the value proposition of tarcocimab, and walk through what the profile of that drug looks like, particularly against what everybody knows here in Europe and abroad from Roche and Regeneron with high-dose EYLEA. Talk a little bit about your drug and what was so exciting about the results.
Yeah. Thanks, Michael. Well, the journey of the anti-VEGF class obviously goes back more than 20 years. Since that time with Lucentis and EYLEA, with the monthly dosing or the every other month dosing, the journey has been about, well, how do we get that efficacy? How do we get that immediacy? At the same time, how do we get a better durability so that we can give fewer doses over time? That has been a holy grail in the sector. 20 years later, starting in maybe 2004, 2005, 2006, nobody was able to do that.
People began to think, "Well, maybe a biologic can't do that, so maybe you need to have something more exotic like a gene therapy or some sort of drug delivery port or some system." We began the journey a number of years ago to try to solve that problem, and it's a very difficult problem. We developed our ABCs or our antibody conjugate technology, and then we've been testing that with tarcocimab in different ways. The framework that I like to think about is this sort of four-quadrant plot where you have the efficacy, immediacy on the Y-axis and the durability on the X. Where you want to be is that upper right quadrant where you have the same efficacy, immediacy as EYLEA and Lucentis, let's say, and you want to have a definitively different kind of durability.
I think when we went into the DAYBREAK study, and we didn't know, well, what could we show, right? We needed to have that efficacy and immediacy of the Lucentis or EYLEA, and we wanted to try to have a better durability. Obviously in the field, Roche did their best attempt, and with Lucentis, then they were able to develop Vabysmo, which didn't really deliver on the scientific concept of the bispecific mechanism with the Ang-2.
The label, I think, says, "No clinical benefit of Ang-2 was shown." Perhaps it did show some incremental durability, or maybe from a variety of different perspectives, it had maybe incrementally better from a variety of perspectives than, say, EYLEA. Regeneron's attempt to solve the problem, to try to get into that upper right quadrant, was to develop higher-dose EYLEA HD. It, again, is fairly incremental vis-à-vis EYLEA. Vabysmo and EYLEA, we kind of term them as Gen 1.5 agents, and they're just definitively not in that upper right quadrant. Going into DAYBREAK, which was, I think, a study design where we brought a lot of conservatism in terms of the study, but also some new ideas about how we should design the study.
We didn't know before the readout, and running these phase III studies in treatment-naive wet AMD against EYLEA, which is a strong comparator, it's very hard to see what's really happening in the study. I think we were quite measured in advance of the readout.
And we're saying, "Well, maybe we could be a little bit more incrementally better than HD and Vabysmo. Maybe our immediacy could be a little weaker maybe than EYLEA, and that still would be good. Maybe we could be on the edge of the upper right quadrant. Maybe that would be very good." And I think obviously we were very surprised. I mean
You were in the upper right-hand quadrant.
Yeah, we're
So, yeah. So, basically, to summarize for investors, if you haven't taken a look at this data, you basically showed the immediacy right on top of the curves of EYLEA. Tell us about your durability.
Yeah. The immediacy is either the same or maybe better, both in terms of the OCT and the fluid control, and also the powerful vision coming out of your starting point. At the same time, we did four loading doses, and coming out of that, we brought essentially, initially 48% of the patients to six-month dosing, and through the endpoint, more than half the patients. There is a lot of, I wouldn't really call it trickery, but a lot of different approaches that sponsors take to try to push durability in different ways. It is important when you interpret studies from Regeneron with HD or Roche with Vabysmo to understand, well, how they define durability in the study. We decided because with tarcocimab, let's not use any gimmicks. Let's try to use retreatment approaches that are as close to what the physicians do in their practice.
What the physician does is they take the OCT image of the fluid of the eye, and they just kind of print it out and put it next to the patient. A photographer does that, and then the physician comes in, and then they look, and if they see any fluid there, they are going to treat the patient.
Right.
We established a methodology to do that, whether it is AI or whatever you want to call it. It was just designed to provide a consistency across the study, and it was kind of calibrated where it was very close to the sensitivity limit of the machine.
Yeah.
If fluid is definitively there, close to the sensitivity limit of the machine, then we would treat the patient.
Basically, you have five-month average dosing, 48 people, what was the number you gave? 48% of people are getting to six months?
Yeah. More than half, yes.
You have at least one-month gain of durability over high-dose EYLEA and all these other things, and I won't even try to cross-talk compare, but it wasn't like, "Oh, you got an extra." But you're using an extra month, and it was using the most stringent retreatment criteria. A lot of these older studies that people are looking at were getting the four months, but they were using retreatment criteria where they had a certain amount of OCT increase. I can't remember. It depends from study to study. Or letters of loss.
Or both, usually.
Yeah.
Nobody does that in clinical practice. The retinal specialist looks at it, "Ah, there's a little bit of fluid," immediately redose, and that was the type of criteria.
Yeah, what's amazing really is the results.
Most stringent criteria.
The results are so strong in the efficacy and the immediacy and the durability, so impressive. We capped the dosing so that the patients couldn't go longer than six months.
Yeah.
But, the majority of the patients didn't meet the criteria even at six months.
Yeah.
So the durability is probably even stronger in some way, and it's very nice to have a science hypothesis because we know that when you inject our drug in humans, really it's a half-life of 20 days average. But it's quite interesting that it can range from a 10-day half-life in some patients all the way to
Yeah
a 50-day half-life in other patients. So we have really a science-based support for the agent's
Yeah
behavior in the study, and also related to an improvement, let's say, in the formulation that we made where we've mixed some of the free antibody together with the conjugated antibody.
Yeah.
That sort of next-generation version of the formulation really delivered the very special results.
This AMD data was just presented at the major medical conference. Can you talk about maybe a couple of the key takeaways? Obviously, I listened to the webcast and heard Charles Wykoff, we heard David Brown. These are some of the most renowned KOLs
Yeah
in the country. What were the sort of two or three key takeaways that investors would say, "Wow, wait, what is the peak sales? What is the uptake of this drug going to be?
Well, I do think they were pretty clear that they thought the results were a home run and that the molecule itself is a home run, and that it does represent a new class and a new promise for their patients and for all patients.
I thought they said new standard of care was what they-
Yeah, a new standard of care. That would be quite something.
Yeah.
So
We have some of the biggest KOLs talking about this new standard of care. Where are you then with this program in terms of regulatory filing? What is the status of this program?
Yeah, it is quite exciting after the number of years of work. We are compiling the BLA across the three different diseases of wet AMD, diabetic retinopathy, and also retinal vein occlusion. Major areas within the anti-VEGF class. We are on track, I believe, to file the BLA for that this year. That could be approved, I believe, in 2027.
Okay. What are the I would have to check my Roche and Regeneron analyst. I see Matt in the back there. Where are we with peak sales of the class right now? I am just thinking about market share and what the peak sales of this drug could be.
Well, I think the EYLEA HD franchise is north of $8 billion , I believe.
Yeah.
I think the Vabysmo, Lucentis franchise, Vabysmo, I think, is trending north of $5 billion. People think it is going to go to $7 billion-$8 billion.
Okay.
Certainly it is a class in and around $15 billion.
Okay.
Yeah.
$15 billion peak sales consensus for the class. Your product launching in 2027 could take a meaningful share of that, going against some reputable commercial companies.
Yeah.
How are you going to do that? Is Kodiak itself going to go do that? What is the actual message to investors in terms of Kodiak going to go try and launch this product themselves against Regeneron and Roche?
Well, obviously it is a great question. We are continuing to build the company. The focus right now is filing the BLA for tarcocimab, reading out the other program that we will talk about, the KSI-101 later this year, and focus on the BLA for that program.
Yeah.
I do think pharma commercial or biopharma commercial is under a lot of pressure, a lot of forces. In the U.S., retina is a fairly focused area, so it is credible for a small company-
Okay
I believe, especially with medicines like ours, tarcocimab, and also KSI-101 program. Both of them should be powerfully differentiated in their markets.
Yeah.
I think 101 should be a drug that sells itself, I believe. Although Zenkuda, tarcocimab, is selling into a more complicated commercial area, I think our molecule, from the standpoint of our science, our differentiation story, the data that we've generated, I do think that especially the combination of those two provide us something very special to be able to sell in the buy and bill, with attractive pricing and thoughtful-
Yeah
fairly agile commercial capability.
Oh, look, you have Regeneron, you have Roche as a dominant share. Interestingly enough, in the last month, Merck reported some data. They have reiterated their continued interest in this space. They obviously have a Wnt program they have been interested in that was through an acquisition. We will see how that program plays out, but they have had some bullish comments about the space. Yesterday, J&J just announced an acquisition of another company in the space as well. To me, it looks like there are people that continue to be very focused in retinal.
Yeah, I think what is special also about Kodiak is our deep capability in discovery and development.
Okay.
We also have our co-owned facility for commercial manufacturing.
Right
Ursus, that is Swissmedic approved.
Right.
So-
Just yesterday, can you clarify that? Because this is a really important thing that you've been working on the last few years. Where is this manufactured? This has all been scaled up. Can you talk a little bit about that?
Yeah, we make our antibodies in the U.S., and we make our conjugates in Switzerland.
Okay.
The facility that we use for that is a Kodiak co-owned facility that's dedicated to the manufacturing of our ABCs.
Okay.
Can provide whatever commercial supply-
Right
is needed.
You have your own site. This is not third party. This is your own site that's been-
Well, it's co-owned.
Co-owned.
We funded-
Yeah
funded the CapEx. We have our team. We are part of the Swissmedic approval team.
Okay.
Okay. All right. The point about this is, and this all just happened over the last 12 months, and quite frankly, the major AMD data was just a couple months ago. This is when the stock went up a lot, and so I just want to refresh, because this was all very new and pretty remarkable that this data came out in AMD. If all that was not enough, that you have a multi-billion dollar drug potentially on your hands, we are all eagerly awaiting data on the second franchise, which is a VEGF IL-6 bispecific, and this is for MESI, and also can be developed for DME and other indications, so we do not want to get too complicated here. But explain what this MESI indication is, and explain what the IL-6 bispecific could do in MESI.
Yeah. Well, MESI is macular edema secondary to inflammation.
Okay
in the eye, and it really reflects the immune system, sort of an autoimmune attack against the retina and against maybe the barrier of the blood, retinal barrier.
Okay.
There's maybe 10 or 50 or 100 different causes of why the body would do that.
Okay.
Whether you got a tattoo and then the pigment in your immune system attacks that and it cross-reacts, or maybe you had your appendix removed and you have sort of a post-surgical attack that happens, or whether you have juvenile idiopathic arthritis as a child and the immune attack against the arthritis then cross-reacts against the retina. There's many, many causes, historically, different uveitis specialists together with your systemic rheumatologist might try to discover what that proximal catalyst of this
Okay
was, then they would try to address that. What's amazing about our medicine is it's really a drug that seems to be working very powerfully and very immediately against the ocular pathology from all of these different sources.
Because you have an anti-IL-6?
Yes.
Yes.
Yeah. The anti-VEGF helps anti-IL-6. Together, it must be some synergistic effect, maybe that we do not totally understand, but the combination of those, it is sort of a 1 + 1 = 7
Yeah
kind of concept, and you see it right away. It is a unifying therapy, and you no longer need to have large teams, and a lot of it is just retina. Retina doctors treat macular edema.
Yeah.
Macular edema is just a physical thing that you can see on the OCT. Then they do a lot of that treatment with wet AMD, it is fluid, and they do it with macular edema for diabetes, with DME, they do it in retinal vein occlusion.
Yeah.
MESI is, in some way, it is not wet AMD, DME, or RVO, it is macular edema, and you may have inflammation or you may have proximally had some cause that led to the inflammation.
So-
It is kind of actually a fairly large set of patients that is quite surprising.
Now, you put some slides on this, so just for an estimate, you think there is approximately about 200,000 patients in the U.S. that have-
Yeah, I think we calculated different epidemiology and stuff, maybe looking at it from different ways to is the initial addressable market, say, around 150,000.
150. What investors have also learned in the last year or two is that Roche has an anti-IL-6, vamikibart. They have reported and presented phase III data for uveitic macular edema, a similar indication, and they have reported phase III data. Can you explain what we have learned from that, how you feel about your drug compared to vamikibart? Ultimately, once we understand that, we'll talk about your phase III that's coming up. So what do we know about vamikibart? What do you think about that result?
Yeah, the Roche drug is an anti-IL-6 antibody alone.
Okay.
As a result of that, they've defined their indication in a more narrow way.
Okay.
They have more excluded types, and they kind of have a narrow view. The drug was impressive in the phase I/II studies.
Okay.
There are currently intraocular injected steroids is how you treat these patients.
Okay.
When you do that, a large number of these patients will have a permanent glaucoma that emerges over time, and then that will lead to many different types of surgeries, and it's really the beginning of kind of a downhill spiral for the patients.
Okay.
Therefore, their data was impressive, and they also tested that antibody, the IL-6, in DME. But I guess I would say that the antibody maybe has some liabilities, and led to some different types of inflammation at higher doses
Okay
mostly in the DME population.
Okay.
They therefore tested the two lowest doses in the kind of MESI equivalent disease in their UME studies.
Okay.
They had one successful phase III readout and one failed phase III readout. They have spoken with FDA, and they are going to file on their 0.25 mg, their lowest dose. They filed, and they have a PDUFA, they said, for July of 2027.
Okay. Roche vamikibart filed on a mixed package where they have one positive phase III, and the second phase III, it missed on the high dose. It is technically statistically significant, although I guess it is the lower dose. I do not know if they call that nominal-
Right
statistically significant, but it was not. They tested the high dose first. I do not know if they split it or how they looked at that. In general, the low dose worked. Now, in that result, which they have filed to the FDA and have a July PDUFA date, they have a primary endpoint where they used three-line gainers, but they also did look at BCVA letter improvement in uveitic macular edema. Your study is in MESI, and your primary endpoint is BCVA letter improvement. What would investors expect in your study? A, I assume you think it is positive, and B, what is positive results compared to what we already have from Roche, which is, I will save everybody the analysis, approximately five to eight letters placebo adjusted? You tell me what you think, but our math says five to eight letters.
So, what is a positive result for Kodiak, and define what you think is going to happen?
Well, this year, this will be our third top-line data readout phase III. I think in advance of the first one, I think the GLOW2, we said we thought we were going to have a solid readout, and it was even stronger than we thought.
Okay.
In advance of the DAYBREAK readout, to be honest, we were not sure. We were pretty measured. We said it is against a strong active comparator, and it is hard to really see what is happening. We are not sure. We are hopeful. I think in advance of this readout, we are very confident, and we are very optimistic. We think we are looking at something special. The data will be available before Christmas, and it is going to be, I think, very exciting. These are very sick patients. The drug is incredibly powerful, incredibly strong, very immediate and packs a big punch. We're testing a 5 mg dose and a 10 mg dose against placebo, sham, essentially. And we've enriched the patients in the pivotal program design where we have what's called the PEAK study cohort one, and we have PEAK study cohort two. Those are really the
Yeah
very sick patients within this population that really have the ability to have a lot of fluid, and their vision is highly deteriorated, and they have relatively low vision to start with.
Yeah.
They have a lot of room to pop in terms of vision gain. And then we have sort of a less sick population that we call PINNACLE, which is more of a safety study concept. And the first readout, yeah, is before Christmas, and then we'll have another readout, let's say, in the May timeframe
Okay
for the two. And I think the primary endpoint is the mean change in vision, and then we pop through that, and I guess I would expect very strong gains. Hopefully, we could be looking at north of 10 letters. Obviously, we don't
Oh, north of 10 letters.
know, but let's see. The most important regulated endpoint really is the three-line gain, the 15-letter gain.
Right.
It's more of a responder/non-responder analysis.
Yeah.
I think we also have six loading doses once a month and the endpoint at week 24, and we're really giving time for the retina to kind of repair.
Yes
to really pop the vision.
Yes
in the patient. Versus the vamikibart, obviously, it is very difficult to do the cross-trial type comparisons, but we have seen very, very strong and immediate fluid control, even within the first week.
Yes.
Essentially normalizing the retinal architecture. It does not matter what the proximal cause is, as I mentioned earlier.
Yes.
I think in one of our presentations from the phase I/II, we even shared every OCT from every patient.
Yes
I think at the high dose, at baseline, then like week 16 or something. It is very, very strong, irrespective. I think we are very optimistic about the readout. I think the disease is actually a lot more prevalent. A lot of the enrollment that we have seen is coming out of retina practices, which is exciting, not just the uveitis practices. Once the retina physicians understand what the profile is of MESI, which is macular edema that is not wet AMD, not DME or RVO, then they say, "Oh, well, I have 100 patients waiting for injections today."
Yeah.
They go back and do a little mini chart review. They are finding, "Oh, 20 of these patients are MESI patients." That is why we have been able to enroll, even though we tripled the size of the pivotal program.
Right
To make sure that it is going to be successful, we are able to enroll those 900 subjects really at the same rate that we thought we might be enrolling the 300 subjects.
Roche's vamikibart, which is the first positive readout for a similar related indication, uveitic macular edema, showed five to eight letters of BCVA placebo-controlled delta, if everybody can remember that. When we look back at your result, cross-trial in phase I and phase II, you were showing, in a nutshell, 50% better efficacy, cross-trial comparison. But importantly, the biology of it was that you have immediacy of the drying on the OCT, a nd that was actually a key competitive advantage, that there's a biology supporting this result. And that is because you're using an IL-6 with a VEGF bispecific.
Right.
And you think, A, I don't know about the IL-6 and how potent it is versus theirs, but that the VEGF component of it, as a bispecific, could be aiding in drying the eye out. Do you think there's biology and specific engineering that makes your molecule better?
I think so.
and that's why you will do north of-
Yeah, it's an attractive. It's a great protein. When you're doing drug development, then when you have a very good material, like a good clay, the Zenkuda product, the tarcocimab, as the new formulation is just incredibly stable, which we're very proud of, and that's fantastic. With the KSI-101 product, the protein is just clearly an amazing drug substance, and very powerful, and it must be that the combination of the two mechanisms in this indication is very powerful. Roche, they had maybe more of a, I guess I would say, a more of a wounded substance that they're working with.
They did the best that they could in their SANDCAT and MEERKAT studies.
Right.
They also had a sham rate of response that kind of crept up and destroyed their high dose, and they had sort of an inverted dose response curve, which is, you always wonder when you have an inverted dose response, what is that?
Right.
I think in our case, our 5 mg dose is very strong, and the 10 mg dose also very strong.
Yeah.
If you're looking at responder versus non-responder, I think, if you look at the sicker patients in the phase I/II study, sort of what we call the PEAK equivalent population that we're now studying in these two pivotals, that's really the group that had, let's say, north of 50% responder rate.
Right.
I think we're hoping that we can replicate that in the phase IIIs, and then to keep our placebo rates quite low, certainly in the single digits.
Right. The three-line gainer numbers was north of 50% in the earlier studies.
That is right.
This is a huge bar, and you should not expect much in the placebo.
Correct.
What about safety?
Well, what is nice is in the anti-VEGF area, you really need to have close to pristine safety because EYLEA and Lucentis have very good safety. In the MESI area, these patients, safety is, I would not say it is less important, it is just that these patients have inflammation already. They have a more angry eye to start with. Also, there are no approved therapies other than intraocular steroids that are actually very dangerous over time. So it, the benefit-risk is a very different kind of calculus.
Right.
There is nothing there. We are delivering the first biologic for the patients. These patients are very sick and on a very complex trajectory of blindness, and so safety is less relevant in this case.
What is even the Because I thought about this. I am like, when you deal with AMD, I think we have done it for now 10 or 15 years, we have looked at all these major phase III AMD studies, everyone is worried about things like intraocular inflammation, is what had a lot of problems for a lot of drugs. Remember Beovu? And your drug showed remarkable, tarcocimab, remarkable safety. That was part of why your stock went up 170% that day. With this is in MESI, they are starting with inflammation.
Right.
Then, you are administering IL-6, which is an anti-inflammation drug. What side effects or what adverse events would even be notable? None? What is-
Yeah, I think what you do not want is what the vamikibart molecule has a little bit of, which is where you have sort of an immune attack against the drug in the eye.
Right.
That's not very good, and that could maybe lead to more of a class of blinding inflammation. I think we don't anticipate any of that. As I said, that's really a function of kind of the sequence or the clay of that fundamental drug substance. I think we have a very clean drug substance.
Okay.
Yeah. We're looking for very nice safety and very strong efficacy.
Okay.
Yeah. We're looking to have that product in a BLA. This is the first pivotal readout. The second pivotal, which is a carbon copy of this,
Yes
that's almost fully enrolled, probably will be fully enrolled certainly this year, and that's a 24-week endpoint. So we'll see top-line data from the second pivotal, let's say, in May, June of this year.
Now, in the last minute or so, if I can recall, Roche is now sort of following the same trajectory because they also started an IL-6 VEGF bispecific. Is that correct? They are trying to do DME. Are you also trying to do DME? I mean, the two points was, one, Roche has now started a sort of a program on a bispecific.
Well, I do not know what the progress is of their small-
I do not know what is going on there.
I believe they are progressing their DutaFab program.
Okay.
Which is sort of a, I would say, reasonably highly mutated Fab fragment that is designed to bind two different targets. That is quite small. We are developing the KSI-501 asset, which also had a very nice readout in DAYBREAK, very successful in the wet AMD, and that molecule is being explored in the phase III ALTO study, and that is accelerating well. We are enrolling and randomizing a good number of patients.
Yeah.
I think we are ahead, and that is a conjugated ABC with a mix of the free protein and the conjugated protein.
2026 has been noted as one of the biggest capital-raising years in biotech in the last five years, and yet your stock is up north of 250% this year, and you have not done a financing after two positive phase II readouts. The stock was up 170%. You did not do any financing. Why is that?
Well, we did set up a shelf after DAYBREAK, and we set up an ATM. We did a small $70 million-
Off an ATM.
offering off an ATM, like a week or two ago. I think we're looking at our company and saying, "Well, what is the CapEx table evolution?" If you look at a $15 billion biotech or a $25 billion biotech, who are the holders that own 5%-20% of those companies?
Okay.
We're really involved in some education and engagement with those investors.
Okay.
We're really thinking about how we evolve our shareholder base to those investors. That was part of the ATM transaction that we did a couple of weeks ago.
Okay.
Coming after the PEAK readout later this year, we are looking at doing a more traditional financing that will kind of capitalize Kodiak, say, through the maybe the next 18 months. I think what is important is that at Kodiak, over the many years, we are very disciplined.
Yes.
We do not blow out the cap table, and we try not to over-raise.
Right.
We try to do things in sort of a metered fashion.
Right
Consistent with kind of our operational progress. I think we will try to continue that, and I think that has been good for shareholders.
It's interesting, back in the spring, in March, when you reported out that day, the stock was up like 50%, and people were like, "Well, how come you're not doing a financing?
Yeah.
Now the stock's 110. "Oh, well, how come we haven't done a financing?
Right. Just remarkable.
Yeah. We look forward to these results, I guess you said before Christmas.
Yeah.
Congratulations on the success, and look forward to continued execution in 2027. Thank you.
Perfect. Thanks, Michael.
Thank you.